MiRagen enters $5M partnership with Leukemia & Lymphoma Society
BOULDER — MiRagen Therapeutics Inc. (Nasdaq: MGEN), a biopharmaceutical company focused on RNA-targeted therapies, and The Leukemia and Lymphoma Society have entered into a collaboration and funding agreement.
The partnership will support the development of miRagen’s drug cobomarsen, also known as MRG-106, a microRNA-155 inhibitor for patients with a certain type of T-cell lymphoma. The type, called mycosis fungoides, affects about 16,000 to 20,000 people in the U.S.
The Leukemia and Lymphoma Society will provide up to $5 million through the purchase of miRagen common stock to support the drug through its clinical trial. That includes a $1 million investment upon signing the agreement and additional stock purchases upon achieving certain milestones. Funding from LLS is provided under its Therapy Acceleration Program, a strategic initiative where LLC partners directly with biotech companies. LLS will also provide patient support and education.
SPONSORED CONTENT
The many benefits of simple, coordinated healthcare
Kaiser Permanente combines health care and coverage in one connected system to maximize employee health and minimize employer costs.
BOULDER — MiRagen Therapeutics Inc. (Nasdaq: MGEN), a biopharmaceutical company focused on RNA-targeted therapies, and The Leukemia and Lymphoma Society have entered into a collaboration and funding agreement.
The partnership will support the development of miRagen’s drug cobomarsen, also known as MRG-106, a microRNA-155 inhibitor for patients with a certain type of T-cell lymphoma. The type, called mycosis fungoides, affects about 16,000 to 20,000 people in the U.S.
The Leukemia and Lymphoma Society will provide up to $5 million through the purchase of miRagen common stock to support the drug through its clinical trial. That…
THIS ARTICLE IS FOR SUBSCRIBERS ONLY
Continue reading for less than $3 per week!
Get a month of award-winning local business news, trends and insights
Access award-winning content today!